{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:40:02Z","timestamp":1738237202516,"version":"3.34.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To assess adherence to medical follow-up protocols among BRCA1\/2 carriers and compare outcomes between dedicated carrier clinics and community healthcare settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This cross-sectional study was conducted by distributing an anonymous questionnaire within the \u2018Good BRCA Genes \u2013 Support and Information Group for BRCA Carriers\u2019 association. The questionnaire assessed adherence to recommended surveillance and satisfaction with various aspects of the follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 682 BRCA carriers surveyed, 68.5% reported fully adhering to recommended medical follow-up. Those not fully adhering cited bureaucracy challenges, scheduling difficulties, timing uncertainties, and difficulty remembering examination dates. Less than 50% were satisfied with appointment availability, scheduling, contact persons, and general practitioners\u2019 knowledge of BRCA carrier risks and follow-up. The 417 women monitored in dedicated breast clinics reported notably higher optimal adherence to recommended surveillance (78.3 vs. 53.6%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.0001). In addition, they noted greater satisfaction with appointment availability (63.7 vs. 25.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.0001), appointment scheduling process (58.1 vs. 24.7%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.0001), availability of breast surgeons\/gynecology specialists (67.4 vs. 50.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.0001), and availability of a contact person for consultations between appointments (53.5 vs. 20.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Our findings highlight the advantages of surveillance in dedicated BRCA1\/2 clinics, including closer monitoring and increased satisfaction. Given the limited availability of such clinics and the growing number of BRCA1\/2 carriers, the opening of additional dedicated clinics and the consideration of alternative surveillance-enhancing solutions, such as training healthcare professionals, using digital tools, and employing artificial intelligence, are essential.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000904","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:09:22Z","timestamp":1718298562000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Compliance and satisfaction with BRCA surveillance in specialized clinics versus community follow-up"],"prefix":"10.1097","volume":"34","author":[{"given":"Rita","family":"Vortman","sequence":"first","affiliation":[{"name":"Neonatal Intensive Care Unit, Rambam Health Care Campus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moran","family":"Echar","sequence":"additional","affiliation":[{"name":"Genetics Institute, Carmel Medical Center, Haifa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amihood","family":"Singer","sequence":"additional","affiliation":[{"name":"Community Genetics, Public Health Services, Ministry of Health, Jerusalem"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Sagi-Dain","sequence":"additional","affiliation":[{"name":"Genetics Institute, Carmel Medical Center, Haifa"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"R1-20250130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1897-4287-2-2-77","article-title":"Developments in clinical practice: follow up clinic for BRCA mutation carriers: a case study highlighting the \u2018virtual clinic\u2019.","volume":"2","author":"Ardern-Jones","year":"2004","journal-title":"Hered Cancer Clin Pract"},{"key":"R2-20250130","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jmg.2009.072728","article-title":"The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.","volume":"47","author":"Bancroft","year":"2010","journal-title":"J Med Genet"},{"key":"R3-20250130","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention.","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"R4-20250130","doi-asserted-by":"crossref","first-page":"9873954","DOI":"10.1155\/2020\/9873954","article-title":"Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1\/2: a Review of Secondary Prevention Guidelines.","volume":"2020","author":"Dullens","year":"2020","journal-title":"J Oncol"},{"key":"R5-20250130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10689-012-9530-x","article-title":"A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.","volume":"11","author":"Engel","year":"2012","journal-title":"Fam Cancer"},{"key":"R6-20250130","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of web surveys: the checklist for reporting results of Internet E-surveys (CHERRIES).","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J Med Internet Res"},{"key":"R7-20250130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/pon.1846","article-title":"Novel one-stop multidisciplinary follow-up clinic for BRCA1\/2 carriers: patient satisfaction and decision making.","volume":"20","author":"Firth","year":"2011","journal-title":"Psychooncology"},{"author":"Isaacs","journal-title":"UpToDate","article-title":"Cancer risks and management of BRCA1\/2 carriers without cancer.","key":"R13-20250130"},{"key":"R8-20250130","first-page":"18","article-title":"Variations in practice and geographic disparities between dedicated multidisciplinary clinics for BRCA1\/BRCA2 mutation carriers in Israel.","volume":"25","author":"Hermann","year":"2023","journal-title":"Isr Med Assoc J"},{"key":"R9-20250130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10689-010-9333-x","article-title":"Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1\/2 carriers.","volume":"9","author":"Pichert","year":"2010","journal-title":"Fam Cancer"},{"key":"R10-20250130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"key":"R11-20250130","first-page":"549","article-title":"A dedicated follow-up clinic for BRCA mutation carriers.","volume":"18","author":"Yerushalmi","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"R12-20250130","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae057","article-title":"Factors influencing adherence to the risk management program for women with a genetic predisposition to breast cancer: real-world data from a French Multicenter Program.","author":"Zhou","year":"2024","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:02:43Z","timestamp":1738234963000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000904","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"type":"print","value":"0959-8278"},{"type":"electronic","value":"1473-5709"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}